Medical - Devices
Compare Stocks
5 / 10Stock Comparison
INSP vs NVCR vs TNDM vs IRTC vs MDT
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Devices
Medical - Devices
Medical - Devices
INSP vs NVCR vs TNDM vs IRTC vs MDT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices | Medical - Devices | Medical - Devices |
| Market Cap | $1.31B | $1.92B | $1.27B | $4.10B | $99.94B |
| Revenue (TTM) | $915M | $674M | $1.03B | $788M | $35.48B |
| Net Income (TTM) | $131M | $-173M | $-95M | $-28M | $4.61B |
| Gross Margin | 85.8% | 75.2% | 54.9% | 71.0% | 61.9% |
| Operating Margin | 5.6% | -27.2% | -7.9% | -3.3% | 17.9% |
| Forward P/E | 24.5x | — | — | — | 14.1x |
| Total Debt | $32M | $290M | $444M | $731M | $28.52B |
| Cash & Equiv. | $105M | $103M | $91M | $236M | $2.22B |
INSP vs NVCR vs TNDM vs IRTC vs MDT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Inspire Medical Sys… (INSP) | 100 | 55.9 | -44.1% |
| NovoCure Limited (NVCR) | 100 | 25.0 | -75.0% |
| Tandem Diabetes Car… (TNDM) | 100 | 22.2 | -77.8% |
| iRhythm Technologie… (IRTC) | 100 | 100.5 | +0.5% |
| Medtronic plc (MDT) | 100 | 79.1 | -20.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INSP vs NVCR vs TNDM vs IRTC vs MDT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
INSP is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.
- Rev growth 13.6%, EPS growth 179.4%, 3Y rev CAGR 30.8%
- Lower volatility, beta 1.27, Low D/E 4.1%, current ratio 6.08x
- 14.3% margin vs NVCR's -25.7%
NVCR ranks third and is worth considering specifically for momentum.
- +1.1% vs INSP's -70.9%
Among these 5 stocks, TNDM doesn't own a clear edge in any measured category.
IRTC is the clearest fit if your priority is long-term compounding and defensive.
- 379.3% 10Y total return vs INSP's 82.4%
- Beta 0.93, current ratio 4.63x
- 26.2% revenue growth vs MDT's 3.6%
MDT carries the broadest edge in this set and is the clearest fit for income & stability.
- Dividend streak 36 yrs, beta 0.47, yield 3.6%
- Better valuation composite
- Beta 0.47 vs NVCR's 2.20, lower leverage
- 3.6% yield; 36-year raise streak; the other 4 pay no meaningful dividend
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 26.2% revenue growth vs MDT's 3.6% | |
| Value | Better valuation composite | |
| Quality / Margins | 14.3% margin vs NVCR's -25.7% | |
| Stability / Safety | Beta 0.47 vs NVCR's 2.20, lower leverage | |
| Dividends | 3.6% yield; 36-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +1.1% vs INSP's -70.9% | |
| Efficiency (ROA) | 175.8% ROA vs NVCR's -16.5%, ROIC 6.0% vs -16.4% |
INSP vs NVCR vs TNDM vs IRTC vs MDT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
INSP vs NVCR vs TNDM vs IRTC vs MDT — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
INSP leads in 1 of 6 categories
IRTC leads 1 • NVCR leads 0 • TNDM leads 0 • MDT leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — INSP and MDT each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT is the larger business by revenue, generating $35.5B annually — 52.6x NVCR's $674M. INSP is the more profitable business, keeping 14.3% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, IRTC holds the edge at +25.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $915M | $674M | $1.0B | $788M | $35.5B |
| EBITDAEarnings before interest/tax | $62M | -$165M | -$68M | -$6M | $9.4B |
| Net IncomeAfter-tax profit | $131M | -$173M | -$95M | -$28M | $4.6B |
| Free Cash FlowCash after capex | $97M | -$48M | -$4M | $19M | $5.4B |
| Gross MarginGross profit ÷ Revenue | +85.8% | +75.2% | +54.9% | +71.0% | +61.9% |
| Operating MarginEBIT ÷ Revenue | +5.6% | -27.2% | -7.9% | -3.3% | +17.9% |
| Net MarginNet income ÷ Revenue | +14.3% | -25.7% | -9.2% | -3.5% | +13.0% |
| FCF MarginFCF ÷ Revenue | +10.6% | -7.1% | -0.4% | +2.4% | +15.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +1.6% | +12.3% | +5.5% | +25.7% | +8.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -5.0% | -100.0% | +84.8% | +55.7% | -11.9% |
Valuation Metrics
Evenly matched — INSP and MDT each lead in 2 of 6 comparable metrics.
Valuation Metrics
At 9.3x trailing earnings, INSP trades at a 57% valuation discount to MDT's 21.6x P/E. On an enterprise value basis, MDT's 14.3x EV/EBITDA is more attractive than INSP's 19.1x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.3B | $1.9B | $1.3B | $4.1B | $99.9B |
| Enterprise ValueMkt cap + debt − cash | $1.2B | $2.1B | $1.6B | $4.6B | $126.2B |
| Trailing P/EPrice ÷ TTM EPS | 9.32x | -13.80x | -6.08x | -89.83x | 21.60x |
| Forward P/EPrice ÷ next-FY EPS est. | 24.46x | — | — | — | 14.13x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 36.00x |
| EV / EBITDAEnterprise value multiple | 19.11x | — | — | — | 14.32x |
| Price / SalesMarket cap ÷ Revenue | 1.44x | 2.92x | 1.25x | 5.49x | 2.98x |
| Price / BookPrice ÷ Book value/share | 1.74x | 5.51x | 8.01x | 26.16x | 2.08x |
| Price / FCFMarket cap ÷ FCF | 16.73x | — | — | 118.84x | 19.28x |
Profitability & Efficiency
INSP leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
INSP delivers a 18.0% return on equity — every $100 of shareholder capital generates $18 in annual profit, vs $-68 for TNDM. INSP carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to IRTC's 4.79x. On the Piotroski fundamental quality scale (0–9), INSP scores 7/9 vs TNDM's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +18.0% | -50.8% | -68.3% | -20.6% | +9.4% |
| ROA (TTM)Return on assets | +15.2% | -16.5% | -10.0% | -2.8% | +175.8% |
| ROICReturn on invested capital | +6.0% | -16.4% | -10.0% | -5.2% | +6.0% |
| ROCEReturn on capital employed | +6.7% | -28.9% | -11.5% | -4.4% | +7.5% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 5 | 3 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.04x | 0.85x | 2.86x | 4.79x | 0.59x |
| Net DebtTotal debt minus cash | -$73M | $187M | $354M | $495M | $26.3B |
| Cash & Equiv.Liquid assets | $105M | $103M | $91M | $236M | $2.2B |
| Total DebtShort + long-term debt | $32M | $290M | $444M | $731M | $28.5B |
| Interest CoverageEBIT ÷ Interest expense | 418.58x | -96.80x | -15.99x | -1.48x | 9.08x |
Total Returns (Dividends Reinvested)
IRTC leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IRTC five years ago would be worth $15,609 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, NVCR leads with a +1.1% total return vs INSP's -70.9%. The 3-year compound annual growth rate (CAGR) favors IRTC at -0.7% vs INSP's -45.6% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -50.6% | +28.3% | -14.3% | -28.7% | -18.1% |
| 1-Year ReturnPast 12 months | -70.9% | +1.1% | -17.0% | -8.3% | -2.8% |
| 3-Year ReturnCumulative with dividends | -83.9% | -75.7% | -44.8% | -2.1% | -4.2% |
| 5-Year ReturnCumulative with dividends | -76.6% | -91.3% | -78.0% | +56.1% | -27.7% |
| 10-Year ReturnCumulative with dividends | +82.4% | +30.3% | -75.4% | +379.3% | +26.5% |
| CAGR (3Y)Annualised 3-year return | -45.6% | -37.6% | -18.0% | -0.7% | -1.4% |
Risk & Volatility
Evenly matched — NVCR and MDT each lead in 1 of 2 comparable metrics.
Risk & Volatility
MDT is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs INSP's 27.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.27x | 2.20x | 1.45x | 0.93x | 0.47x |
| 52-Week HighHighest price in past year | $163.35 | $20.06 | $29.65 | $212.00 | $106.33 |
| 52-Week LowLowest price in past year | $44.41 | $9.82 | $9.98 | $112.31 | $77.16 |
| % of 52W HighCurrent price vs 52-week peak | +27.9% | +83.9% | +62.3% | +58.9% | +73.3% |
| RSI (14)Momentum oscillator 0–100 | 31.6 | 69.8 | 39.1 | 44.1 | 27.3 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 1.5M | 1.8M | 524K | 7.8M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: INSP as "Hold", NVCR as "Buy", TNDM as "Buy", IRTC as "Buy", MDT as "Buy". Consensus price targets imply 100.4% upside for INSP (target: $91) vs 40.5% for MDT (target: $110). MDT is the only dividend payer here at 3.57% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $91.33 | $33.50 | $31.62 | $193.67 | $109.50 |
| # AnalystsCovering analysts | 27 | 15 | 39 | 19 | 49 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +3.6% |
| Dividend StreakConsecutive years of raises | — | — | — | — | 36 |
| Dividend / ShareAnnual DPS | — | — | — | — | $2.78 |
| Buyback YieldShare repurchases ÷ mkt cap | +13.3% | 0.0% | 0.0% | 0.0% | +3.2% |
INSP leads in 1 of 6 categories (Profitability & Efficiency). IRTC leads in 1 (Total Returns). 3 tied.
INSP vs NVCR vs TNDM vs IRTC vs MDT: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is INSP or NVCR or TNDM or IRTC or MDT a better buy right now?
For growth investors, iRhythm Technologies, Inc.
(IRTC) is the stronger pick with 26. 2% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). Inspire Medical Systems, Inc. (INSP) offers the better valuation at 9. 3x trailing P/E (24. 5x forward), making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — INSP or NVCR or TNDM or IRTC or MDT?
On trailing P/E, Inspire Medical Systems, Inc.
(INSP) is the cheapest at 9. 3x versus Medtronic plc at 21. 6x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — INSP or NVCR or TNDM or IRTC or MDT?
Over the past 5 years, iRhythm Technologies, Inc.
(IRTC) delivered a total return of +56. 1%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: IRTC returned +379. 3% versus TNDM's -75. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — INSP or NVCR or TNDM or IRTC or MDT?
By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.
47β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 373% more volatile than MDT relative to the S&P 500. On balance sheet safety, Inspire Medical Systems, Inc. (INSP) carries a lower debt/equity ratio of 4% versus 5% for iRhythm Technologies, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — INSP or NVCR or TNDM or IRTC or MDT?
By revenue growth (latest reported year), iRhythm Technologies, Inc.
(IRTC) is pulling ahead at 26. 2% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: Inspire Medical Systems, Inc. grew EPS 179. 4% year-over-year, compared to -106. 8% for Tandem Diabetes Care, Inc.. Over a 3-year CAGR, INSP leads at 30. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — INSP or NVCR or TNDM or IRTC or MDT?
Inspire Medical Systems, Inc.
(INSP) is the more profitable company, earning 15. 9% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 15. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDT leads at 17. 8% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — INSP leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is INSP or NVCR or TNDM or IRTC or MDT more undervalued right now?
On forward earnings alone, Medtronic plc (MDT) trades at 14.
1x forward P/E versus 24. 5x for Inspire Medical Systems, Inc. — 10. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INSP: 100. 4% to $91. 33.
08Which pays a better dividend — INSP or NVCR or TNDM or IRTC or MDT?
In this comparison, MDT (3.
6% yield) pays a dividend. INSP, NVCR, TNDM, IRTC do not pay a meaningful dividend and should not be held primarily for income.
09Is INSP or NVCR or TNDM or IRTC or MDT better for a retirement portfolio?
For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
47), 3. 6% yield). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +26. 5%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between INSP and NVCR and TNDM and IRTC and MDT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: INSP is a small-cap deep-value stock; NVCR is a small-cap quality compounder stock; TNDM is a small-cap quality compounder stock; IRTC is a small-cap high-growth stock; MDT is a mid-cap income-oriented stock. MDT pays a dividend while INSP, NVCR, TNDM, IRTC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.